Detalhe da pesquisa
1.
Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancer.
Br J Haematol
; 2024 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38556836
2.
A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant.
Haematologica
; 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38328852
3.
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma.
Am J Hematol
; 98(11): 1751-1761, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37668287
4.
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions.
Am J Hematol
; 98(6): 848-856, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36880203
5.
Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia.
Cancer
; 128(3): 529-535, 2022 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34633671
6.
HIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation.
N Engl J Med
; 390(7): 669-671, 2024 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38354149
7.
Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Biol Blood Marrow Transplant
; 26(6): 1084-1090, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32035275
8.
Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia.
Biol Blood Marrow Transplant
; 26(12): e322-e327, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32866594
9.
Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center.
Biol Blood Marrow Transplant
; 26(2): 292-299, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31536825
10.
Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia.
Am J Hematol
; 95(10): 1193-1199, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32628327
11.
Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients.
Haematologica
; 103(10): 1662-1668, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29903756
12.
Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia.
Biol Blood Marrow Transplant
; 23(4): 618-624, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28087456
13.
Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
Br J Haematol
; 196(6): e71-e74, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34931310
14.
Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status.
Haematologica
; 102(12): 2030-2038, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28971906
15.
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).
Am J Hematol
; 96(6): E196-E200, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33719090
16.
Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
Mol Carcinog
; 53(9): 722-35, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23475695
17.
Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
Am J Hematol
; 94(10): E253-E255, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31259427
18.
Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
Leuk Lymphoma
; 65(3): 372-377, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38164785
19.
The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer.
Int J Cancer
; 132(12): 2730-7, 2013 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23165325
20.
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
Haematologica
; 103(9): e404-e407, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29545346